Pharmaceutical companies were reportedly few and far between at Tuesday’s (Jan. 29) Senate Finance Committee hearing on drug pricing, and that poor attendance has some policymakers fuming, FierceHealthcare reports.
Senate Finance Chairman Chuck Grassley said a number of companies declined invitations to testify, though they said they would engage in private discussions.
“One company said testifying would be a problem because of [a] language barrier,” Grassley said. “I thought we all spoke English? That is not what I mean when I talk about transparency.”
Ranking committee Democrat Sen. Ron Wyden floated the idea of forcing the drugmakers to testify.
“Even if it means using our powers to compel the drugmakers’ CEOs to show up, they are going to come before this committee,” he said.
To read the full report on FierceHealthcare, click here.